

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

IGGO et al

Atty. Ref.: 604-691

Serial No. 10/647,111

Group: 1645

Filed: August 25, 2003

Examiner: Unassigned

For: ANTI-NEOPLASTIC VIRUSES

* * * * *

February 4, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


Attached is a completed Form PTO-1449 listing references in connection with this application. Also enclosed is a copy of each of those references.

The Examiner is requested to initial the attached PTO-1449, and to return a copy of the initialed document to the undersigned as an indication that the listed references have been considered and made of record.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____


Leonard C. Mitchard
Reg. No. 29,009

LCM:lfm
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE

CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.

604-691

APPLICANT

IGGO et al

FILING DATE

August 25, 2003

SERIAL NO.

10/647,111

GROUP

1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,585,254	12/1996	Maxwell et al			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
00/56909	09/2000	WO			
01/64739	09/2001	WO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Deleu, L., et al; <i>J Virol.</i> ; 73:3877-85 (1999); "Activation of promoter P4 of the autonomous parvovirus minute virus of mice at early S phase is required for productive infection".
	Fuks, et al; <i>J. Virol.</i> ; Vol. 70, pp. 1331-1339 (1996); "ras oncogene-dependent activation of the P4 promoter".
	Brunori, M., et al; <i>J. Virol.</i> ; 75:2857-2865 (2001); "Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway".
	Biederer, C., et al; <i>J. Mol Med.</i> ; 80:163-75 (2002); "Replication-selective viruses for cancer therapy".
	Deleu, L., et al; <i>Mol. Cell Biol.</i> ; 18:409-19 (1998); "Opposite transcriptional effects of cyclic AMP-responsive elements in confluent or p27KIP-overexpressing cells versus serum-starved or growing cells".
	Faisst, S., et al; <i>I J Cancer</i> ; 75:584-9 (1998); "Dose-dependent regression of HeLa cell-derived tumors in SCID mice after parvovirus H-1 infection".
	Fuerer, C., et al; <i>Gene Ther.</i> ; 9:270-81 (2002); "Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway".
	Hanson, N.D., et al; <i>J. Virol.</i> ; 65:4325-33 (1991); "Parvovirus NS1 stimulates P4 expression by interaction with the terminal repeats and through DNA amplification".
	Kestler, J., et al; <i>Hum Gene Ther.</i> ; 10:1619-32 (1999); cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses".
	Legendre, D., et al; <i>J. Virol.</i> ; 68:7974-85 (1994); "Targeting of promoters for trans activation by a carboxy-terminal domain of the NS-1 protein of the parvovirus minute virus of mice".
	Maxwell, I.H., et al; <i>Gene Ther.</i> 6:309-13 (1999); "Control of parvovirus DNA replication by a tetracycline-regulated repressor".
	Maxwell, I.H., et al; <i>Hum Gene Ther.</i> ; 4:441-50 (1993); Recombinant LuIII autonomous parvovirus as a transient transducing vector for human cells.
	Maxwell, I.H., et al; <i>Gene Ther.</i> ; 3:28-36 (1996); Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters".
	Roose, J., et al; <i>Biochem Biophys Acta.</i> ; 1424:M23-37 (1999); "TCF transcription factors: molecular switches in carcinogenesis".
	Korinek, V. et al; <i>Science</i> ; 275:1784-7 (1997); Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma [see comments]."

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.